- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.07. | Lobe Sciences Ltd (2): Lobe Sciences schedules AGSM for July 30 | 1 | Stockwatch | ||
| 07.07. | Lobe Sciences Ltd.: Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026 | 407 | ACCESS Newswire | The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with... ► Artikel lesen | |
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 09.06. | Lobe Sciences Ltd (2): Lobe Sciences settles $1.37M in mgmt, director fees | 3 | Stockwatch | ||
| 09.06. | Lobe Sciences Ltd.: Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares | 269 | ACCESS Newswire | Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholdersThe Canadian Securities Exchange has... ► Artikel lesen | |
| 02.06. | Lobe Sciences Ltd.: Lobe Sciences Announces Proposed Shares for Debt Transaction | 411 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen | |
| 07.05. | Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York | 545 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential... ► Artikel lesen | |
| 06.05. | Lobe Sciences Ltd.: Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress | 297 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen | |
| 24.04. | Lobe Sciences Ltd (2): Lobe Sciences cheers U.S. order for novel treatments | 4 | Stockwatch | ||
| 23.04. | Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders | 255 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing... ► Artikel lesen | |
| 21.04. | Lobe Sciences Ltd (2): Lobe Sciences hires Massive Intelligence for IR | 1 | Stockwatch | ||
| 21.04. | Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services | 322 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 20.04. | Lobe Sciences Ltd (2): Lobe Sciences closes $950,000 private placement | 2 | Stockwatch | ||
| 20.04. | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update | 300 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 13.04. | Lobe Sciences launches non-brokered private placement of 14.62M shares at $0.065 | 2 | Seeking Alpha | ||
| 11.04. | Lobe Sciences Ltd (2): Lobe Sciences arranges $950,000 private placement | 2 | Stockwatch | ||
| 11.04. | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | 690 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 25.03. | Lobe Sciences Ltd. meldet verbesserte Finanzlage und gibt strategisches Update bekannt | 462 | IR-WORLD | - Verbindlichkeiten um 81 % reduziert, von 2,35 Mio. $ auf 0,44 Mio. $
- Barmittel um mehr als das 24-Fache gestiegen, von 0,24 Mio. $ auf 5,99 Mio. $
... ► Artikel lesen | |
| 25.03. | Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update | 335 | ACCESS Newswire | Liabilities reduced 81%, from $2.35M to $0.44MCash increased more than 24x, from $0.24M to $5.99MNet working capital improved by $6.1M, from ($2.01M) to $4.05MOutstanding warrants reduced by ~70%, from... ► Artikel lesen | |
| 09.03. | Lobe Sciences names Mirza Rahimani as CFO; succeeds Yong Yao | 1 | Seeking Alpha | ||
| 09.03. | Lobe Sciences Ltd.: Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer | 459 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,199 | +1,79 % | Panik im Milliarden-Markt: Novo Nordisk und Halozyme Therapeutics mit Gegenwind - BioNxt Solutions vor Richtungsentscheidung | Im gigantischen Markt für Medikamente geht es um viele Milliarden. Umso erstaunlicher ist, dass in der Pharmaindustrie nicht nur der reine Wirkstoff entscheidet, sondern immer häufiger, wie Wirkstoffe... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Laufende Fusionskontrollverfahren: Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-85/26Unternehmen:Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen | |
| CYBIN | 6,700 | +0,30 % | H.C. Wainwright reiterates Helus Pharma stock rating on trial enrollment | ||
| ENTHEON BIOMEDICAL CORP | 0,035 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Change of Directors | Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,026 | +57,58 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / July 15, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R)... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics und Bodhi Health weiten den Vertrieb und Verkauf von CurcuWIN QuickStrip Curcumin in ganz Kanada aus | DJ PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) und Bodhi Health weiten den Vertrieb und Verkauf von CurcuWIN QuickStrip Curcumin in ganz Kanada aus
... ► Artikel lesen | |
| QIAGEN | 36,930 | +0,65 % | QIAGEN im US-Ausbruch: Diese Tests rücken in den Fokus | ||
| APOGEE THERAPEUTICS | 134,17 | -0,08 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 80,41 | +26,56 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 292,32 | -7,44 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CG ONCOLOGY | 69,37 | -5,64 % | CG Oncology stock maintained at Buy by H.C. Wainwright on trial data | ||
| ERASCA | 17,550 | -7,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| IMMUNOVANT | 38,490 | -3,99 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| BIONTECH | 81,25 | +0,81 % | Chancen & Risiken bei den Q.2-Kennzahlen - Almonty Industries, BioNTech, Danaher, Pfizer, Sartorius | Die globalen Aktienmärkte bleiben dynamisch, und die fundamentalen Rahmenbedingungen haben sich in den letzten Quartalen rasant verändert. Im heutigen Bericht analysieren wir drei faszinierende Unternehmen... ► Artikel lesen |
Das Unternehmen LOBE SCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.